Re-examining the Optimal Use of Neuromodulators and the Changing Landscape: A Consensus Panel Update
Release Date: March 20, 2020 (Last Reviewed: January 3, 2020)
Expiration Date: March 20, 2021
Time to Complete Activity: 1.0 hour
*This activity expired for credit on March 20, 2021 and is no longer available for credit
This activity is provided by Paradigm Medical Communications, LLC. 
Faculty and Disclosures
Michael S. Kaminer, MD (Chair)
Department of Dermatology, Yale School of Medicine, New Haven, CT; Department of Dermatology, Brown Medical School, Providence, RI; SkinCare Physicians, Inc, Chestnut Hill, MA
Consultant: Evolus, Inc.; Revance Therapeutics, Inc
Investigator: Allergan, Inc.; Galderma Laboratories, L.P.
Sue Ellen Cox, MD
Aesthetic Solutions PA, Chapel Hill, NC
Consultant: Evolus, Inc. Investigator: Evolus, Inc.
Steven Fagien, MD, FACS
Steven Fagien, MD, Boca Raton, FL
Consultant: Allergan, Inc.; Evolus, Inc.; Galderma Laboratories, L.P.; Revance Therapeutics, Inc
Investigator: Allergan, Inc.; Revance Therapeutics, Inc
Joely Kaufman, MD
Skin Associates of South Florida/Skin Research Institute, Coral Gables, FL
Consultant: Allergan, Inc.; Evolus, Inc.; Galderma Laboratories, L.P.; Revance Therapeutics, Inc
Investigator: Allergan, Inc.; Evolus, Inc.; Galderma Laboratories, L.P.; Merz North America, Inc.
Patents/Intellectual Property Rights: Toxin for wound healing (owner)
Mary P. Lupo, MD
Lupo Center for Aesthetic and General Dermatology, New Orleans, LA
Consultant: Allergan, Inc.; BELLUS Health Inc; Evolus, Inc.; Merz North America, Inc.; Revance Therapeutics, Inc; Revision Skincare; Solta Medical/Valeant Pharmaceuticals International, Inc; Theraplex; TopMD Skin Care Inc
Speaker: Allergan, Inc.; Envy Medical, Inc.; Lumenis; Merz North America, Inc.; Theraplex
Investigator: Allergan, Inc.; ChemoCentryx, Inc.; Endo Pharmaceuticals Inc; Evolus, Inc.; Merz North America, Inc.; Novan, Inc.; Revance Therapeutics, Inc
Stockholder: ALPHAEON Corporation; Evolus, Inc.; Strathspey Crown; TopMD Skin Care Inc
Trainer: Allergan, Inc
Ava Shamban, MD
AVA MD, SKIN FIVE, Los Angeles, CA
Consultant: Allergan, Inc.; Galderma Laboratories, L.P.; Merz North America, Inc.; Revance Therapeutics, Inc
Investigator: Allergan, Inc.; Brickell Biotech, Inc.; Endo Pharmaceuticals Inc.; Galderma Laboratories, L.P.; Merz North America, Inc.; Revance Therapeutics, Inc; Teoxane Laboratories
Stockholder: Allergan, Inc.
Paradigm Medical Communications, LLC staff members have no financial relationships to disclose.
Peer reviewer, Giuseppe Militello, MD, has the following relationships to disclose: Investigator: AbbVie Inc
Target Audience
This activity has been designed to meet the educational needs of dermatologists, dermatologic surgeons, plastic surgeons, facial plastic surgeons, cosmetic surgeons, ocular plastic surgeons, ophthalmologists, otolaryngologists, nurse practitioners, and PAs. It may also be of benefit to other physicians, nurses, and healthcare providers who are involved in the field of aesthetic medicine.
Learning Objectives
Upon proper completion of this activity, participants should be better able to:
• Review the anatomy and pathophysiology of facial aging as they relate to aesthetic rejuvenation with neurotoxins
• Differentiate available neurotoxins for aesthetic facial rejuvenation, including their indications, preparation, mechanisms of action, efficacy, and safety
• Devise individualized treatment plans for natural, harmonious facial rejuvenation with neurotoxins based on appropriate patient assessment and consultation
Physician Accreditation Statement
Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation Statement
Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PA Continuing Education
PAs may claim a maximum of 1.0 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Disclosure of Commercial Support
This activity is supported by an educational grant from Evolus, Inc.
Instructions for Participation
To receive a CME certificate of participation, you should:
• Read the entire publication, including the CME information.
• Register or log in at www.paradigmmc.com/822 to complete and submit the online posttest and evaluation.
Following online completion of the posttest and evaluation, a certificate of participation will be available for download/printing immediately.
For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949.
There is no fee required for participation in this activity.
Supported Browsers:
For Desktops (Windows/Mac)
Microsoft Edge 40 or higher, Firefox 28 or higher, Safari 5.1 or higher, Google Chrome 31 or higher, Opera 21 or higher
For Tablets (iPad/Android/Surface)
iOS Safari 4 or higher, Android 2.3 or higher, IE Mobile 10 or higher
Adobe Reader
This activity is in Adobe Acrobat PDF format. To view the activity, you will need Adobe Reader. If you do not have Adobe Reader installed on your computer, please visit http://get.adobe.com/reader/ to install a free version of Adobe Reader.
Resolution of Conflict of Interest
Paradigm Medical Communications, LLC has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair and balanced, independent, and aligned with the public interest. Conflicts, if any, are resolved through one or more processes. All CME content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Commercial Support of Continuing Medical Education.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.
Disclaimer
This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.
As an ACCME-accredited provider, Paradigm Medical Communications, LLC activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.
Terms of Use and Privacy Policy
Disclaimer
The materials provided for this activity are for informational purposes only, and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. Any views or opinions presented are solely those of the Faculty, and do not necessarily represent those of Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC accepts no liability for the content referenced in this activity.
Privacy policy
Paradigm Medical Communications, LLC or hosted contracted partner is committed to protecting the privacy of those who participate in the activities located at www.paradigmmc.com (herein referred to as “website"). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.
Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.
Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.
Contact Us
If you have any questions or comments, please email us at contactus@paradigmmc.com.
© 2020 Paradigm Medical Communications, LLC. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.